Vascular Biogenics Ltd (VBLT)

[gr8db8]

davidal66 ... since the company has been through a SPA with rgbm, I think they know the pros and cons about doing it. I suspect they have more confidence in the ovarian results and therefore, need less assurances from the FDA. Not doing a SPA also cuts down on time and costs.

This site sums it up well:
"However, the SPA process can often take several rounds of FDA review before agreement is reached and the FDA may require a more robust trial design than what would have otherwise been considered adequate, which could result in unnecessary delays and increased costs. As with all aspects of drug development, a sponsor should carefully weigh their priorities before entering into an SPA agreement with the FDA."
http://camargopharma.com/2017/04/special-protocol-assessment-important-drug-development-program/